What is Beam Therapeutics's operating lease liabilities?

Beam Therapeutics (BEAM) reported operating lease liabilities of -$3.49M in Q1 2026.

How has Beam Therapeutics's operating lease liabilities changed year-over-year?

Beam Therapeutics's operating lease liabilities decreased by 6.0% year-over-year, from -$3.3M to -$3.49M.

What is the long-term trend for Beam Therapeutics's operating lease liabilities?

Over 4 years (2021 to 2025), Beam Therapeutics's operating lease liabilities has grown at a -4.2% compound annual growth rate (CAGR), from $16.03M to -$13.51M.

Beam Therapeutics BEAM Operating lease liabilities

Operating lease liabilities at other companies

Arrowhead ResearchARWR

——

BridgeBio PharmaBBIO

——

Protagonist TherapeuticsPTGX

——

Viking TherapeuticsVKTX

——

Mirum Pharmaceuticals, Inc.MIRM

——

Other financials

Income statement

See full

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

See full

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

See full

Operating cash flow-$128.5M-23.7%

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

See full

Market cap$3.42B+24.5%

Profitability

See full

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

See full

Return on equity-47.1%—

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Beam Therapeutics's operating lease liabilities?: Beam Therapeutics (BEAM) reported operating lease liabilities of -$3.49M in Q1 2026.
How has Beam Therapeutics's operating lease liabilities changed year-over-year?: Beam Therapeutics's operating lease liabilities decreased by 6.0% year-over-year, from -$3.3M to -$3.49M.
What is the long-term trend for Beam Therapeutics's operating lease liabilities?: Over 4 years (2021 to 2025), Beam Therapeutics's operating lease liabilities has grown at a -4.2% compound annual growth rate (CAGR), from $16.03M to -$13.51M.